Table 1.
Patient characteristics.
| Combined n=200 | Non-DGF cohort n=106 | DGF-cohort n=94 | p-Value | |
|---|---|---|---|---|
| Recipient details | ||||
| Age, years | 55 (±13) | 56 (±13) | 54 (±14) | 0.32 |
| Gender, male (%) | 71 (36) | 46 (43) | 25 (27) | 0.01 |
| Race, n (%) | ||||
| Caucasian, (%) | 72 (36) | 40 (38) | 32 (34) | 0.65 |
| African American, (%) | 128 (64) | 62 (58) | 56 (60) | |
| Weight, kgs | 82 (±20) | 81 (±20) | 83 (±20) | 0.54 |
| Primary aetiology of ESRD | ||||
| Hypertension, n (%) | 59 (30) | 28 (26) | 31 (33) | 0.69 |
| DM, n (%) | 45 (23) | 23 (22) | 22 (23) | |
| Glomerular diseases | 45 (23) | 24 (23) | 21 (22) | |
| Polycystic kidneys | 11 (6) | 7 (7) | 4 (4) | |
| Miscellaneous renal disease | 36 (18) | 22 (21) | 14 (15) | |
| Donor details | ||||
| Age, years | 36 (±16) | 36 (±16) | 36 (±15) | 0.73 |
| Race, Caucasian (%) | 146 (73) | 74 (70) | 72 (77) | 0.55 |
| Gender, male (%) | 74 (37) | 39 (37) | 35 (37) | 0.95 |
| Hypertension (%) | 54 (27) | 30 (28) | 24 (26) | 0.66 |
| Terminal creatinine, mg/dL | 2.0 (0.9–2.0) | 2.0 (0.8–2.0) | 2.0 (1.2–2.1) | 0.08 |
| Clinical data | ||||
| Pre-emptive (%) | 21 (11) | 18 (17) | 3 (3) | 0.001 |
| CDC (%) | 57 (29) | 31 (29) | 26 (28) | 0.67 |
| DCD (%) | 41 (21) | 15 (14) | 26 (28) | 0.03 |
| UFR-Raw, mL/h | 4.5 (0–38) | 9 (0–50) | 0 (0–10) | <0.001 |
| UFR-ABW, mL/kg/h | 0.06 (0–0.4) | 0.11 (0.6 – 1.0) | 0 (0–0.1) | <0.001 |
| CIT, hours | 27 (21–35) | 25 (20–31) | 30 (23–39) | <0.001 |
| Furosemide dose, mg/kg | 1.29 (±0.33) | 1.31 (±0.34) | 1.28 (±0.33) | 0.55 |
| Dialysis first 24h, n (%) | – | – | 55 (59) | – |
| Indication for dialysis within 7 days | ||||
| 1. Hyperkalaemia, n (%) | – | – | 68 (72) | – |
| 2. Volume overload, n (%) | – | – | 14 (15) | – |
| 3. Uraemia, n (%) | – | – | 12 (13) | – |
Continuous variables are presented as mean (± standard deviation) or median (interquartile range) unless otherwise stated. Parametric data were compared with an unpaired t-test. Non-parametric data were compared using the Wilcoxon–Mann–Whitney test. Binomial data were compared using a Persons coefficient. Glomerular diseases include FSGS. membranous nephropathy, Henoch-Schonlein Purpura, Ig A nephropathy, Fibrillary glomerulonephritis, Alports Disease, Wegners granulomatosis. Miscellaneous Renal Disease includes renal cancer including renal cell cancer and myeloma, obstructive uropathy, graft failure and nephrotoxicity. Nephrotoxicity includes analgesic nephropathy, calcineurin toxicity and lithium toxicity. Pre-emptive is defined as, chronic kidney disease stage V who receive kidney transplantation and have not yet started dialysis. CDC: centre for disease control criteria; DCD: donation after cardiac death criteria; DM: Diabetes Mellitus (Type 1 or Type 2); FSGS: Focal Segmental Glomerular Sclerosis; UFR: urinary flow rate; UFR-Raw: baseline UFR prior to transplantation; UFR-ABW: UFR adjusted for body weight; CIT: cold ischemic time; MAP: mean arterial pressure.